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Summary
Dyskeratosis congenita (DC) is an inherited bone marrow failure syndrome
and telomere biology disorder characterized by dysplastic nails, reticular
skin pigmentation and oral leucoplakia. Androgens are a standard thera-
peutic option for bone marrow failure in those patients with DC who are
unable to undergo haematopoietic stem cell transplantation, but there are
no systematic data on its use in those patients. We evaluated haematological
response and side effects of androgen therapy in 16 patients with DC in
our observational cohort study. Untreated DC patients served as controls.
Seventy percent of treated DC patients had a haematological response with
red blood cell and/or platelet transfusion independence. The expected age-
related decline in telomere length was noted in androgen-treated patients.
All treated DC patients had at least one significant lipid abnormality. Addi-
tional treatment-related findings included a significant decrease in thyroid
binding globulin, accelerated growth in pre-pubertal children and splenic
peliosis in two patients. Liver enzymes were elevated in both androgen-
treated and untreated patients, suggesting underlying liver involvement in
DC. This study suggests that androgen therapy can be effectively used to
treat bone marrow failure in DC, but that side effects need to be closely
monitored.
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Dyskeratosis congenita (DC), an inherited bone marrow fail-
ure (BMF) and cancer susceptibility syndrome, is character-
ized by very short germline telomeres and/or a mutation in a
telomere biology gene (Dokal, 2011; Ballew & Savage, 2013).
The diagnostic triad of DC consists of dysplastic nails, reticu-
lar skin pigmentation and oral leucoplakia. Patients with DC
may also have pulmonary fibrosis, liver disease, neurological,
gastrointestinal and ophthalmological problems. In addition,
patients with DC are at a significantly increased risk of solid
tumours, leukaemia and myelodysplastic syndrome (Alter
et al, 2010). Telomere length less than the first percentile for
age measured by leucocyte flow fluorescent in situ hybridiza-
tion (FISH) is diagnostic of DC and differentiates DC from
other inherited BMF syndromes (IBMFS), such as Fanconi
Anaemia (FA) (Alter et al, 2007).
The cumulative incidence of BMF is at least 50% by age
50 years in patients with DC and is often life threatening
(Vulliamy & Dokal, 2006; Alter et al, 2010). Patients with
DC-related BMF do not respond to immunosuppressive ther-
apy (Al-Rahawan et al, 2006). Haematopoietic stem cell
transplant (HSCT) is the only current curative modality for
DC-associated BMF. However, HSCT may not be feasible
due to the presence of co-morbid conditions, lack of suitable
donors or patient preferences; thus, anabolic-androgenic
steroid (androgen) treatment is often considered for DC-related
BMF (Savage et al, 2009; Islam et al, 2013).
Androgens have been used to treat acquired and inherited
BMF, both prior to the current era of HSCT and currently
in patients who are not HSCT candidates (Diamond &
Shahidi, 1967; Allen et al, 1968; Shahidi, 2001; Alter et al,
2010). Historically, BMF in FA patients has also been treated
with androgens with an approximately 50% haematological
response rate (Allen et al, 1968; Shimamura & Alter, 2010).
With recent advances and improvements in HSCT for
patients with FA, androgens are now less often used to treat
FA-related BMF.
The specific mechanism(s) by which androgens stimulate
haematopoiesis is (are) not well understood. It was postu-
lated that androgens lead to an increase in erythropoietin,
which stimulates erythropoietic stem cells and, to a lesser
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extent, myeloid progenitor cells in the bone marrow
(Shahidi, 2001). Recent studies suggest that androgens such
as testosterone do not increase erythropoietin levels, but
rather work at the level of the erythropoietin receptor to
elicit a haematological response (Maggio et al, 2013).
Androgens also stimulate osteoblasts, bone matrix production,
cytokine and growth factor synthesis (Shahidi, 2001).
The most common side effects of androgen therapy
include virilization in females, priapism in males, acne, hepa-
totoxicity including hyperbilirubinaemia, transaminitis, hepa-
tic and splenic peliosis, hepatic adenomas or hepatocellular
carcinomas, lipid abnormalities and behavioural problems
(Shahidi, 2001). Anecdotal data suggest that DC patients are
particularly sensitive to the side effects of androgen therapy;
thus, lower doses and more frequent monitoring have been
recommended (Savage et al, 2009; Islam et al, 2013). How-
ever, androgen-related side effects have not been systemati-
cally studied in patients with DC. Here we describe the
response to androgens and the side effects in DC patients
enrolled in a natural history study of IBMFS.
Patients and methods
Patient characteristics
This retrospective/prospective natural study included patients
with DC enrolled in the National Cancer Institute’s (NCI)
Institutional Review Board-approved IBMFS study (NCI
02-C-0052, NCT00027274, www.marrowfailure.cancer.gov)
between March 2002 and December 2011 (Alter et al, 2010).
Patients were classified as having DC if they had a germline
mutation in one of the known DC genes, or if they had at least
two features of the diagnostic triad and other clinical findings
consistent with DC, such as haematological or neoplastic com-
plications (Savage & Bertuch, 2010; Ballew & Savage 2013).
We reviewed medical records from 16 DC patients who
were treated with androgens, and compared their data with
28 DC patients never treated with androgens (Table I). All
patients underwent evaluations at the National Institutes of
Health (NIH) Clinical Center, and were examined by the
same physicians, whether or not they were on androgens.
The management of patients was at the discretion of their
primary haematologist, with consultative input from the NCI
IBMFS study physicians.
Haematological response was defined as red blood cell
(RBC) and/or platelet transfusion independence along with
an increment in haemoglobin (Hb) of ≥20 g/l from the base-
line, rise in the absolute neutrophil count (ANC) to
≥10 9 109/l without the use of granulocyte colony stimulat-
ing factor (G-CSF), and/or a platelet count increase to
≥40 9 109/l. We evaluated patients for androgen-related side
effects by determining fasting serum lipid profile [total
cholesterol, high density lipoprotein (HDL), low density lipo-
protein (LDL) and triglycerides]; liver function tests (LFT)
including serum bilirubin, aspartate aminotransferase (AST),
alanine aminotransferase (ALT) and gamma-glutamyl trans-
peptidase (GGT); endocrine function [thyroid binding globu-
lin (TBG), triiodothyronine (T3), thyroxine (T4) and
thyroid-stimulating hormone (TSH) levels]. An abnormal
lipid profile was defined as the presence of one or more of
the following: total cholesterol more than 518 mmol/l, LDL
more than 259 mmol/l, triglycerides more than 169 mmol/
l, or HDL <103 mmol/l. LFT values above the normal range
reported by the clinical laboratory were considered abnormal.
Liver and spleen ultrasounds were performed in search of
abnormalities in architecture, peliosis or tumours. Bone age
and linear growth were evaluated in children and adolescents.
Telomere length was determined on leucocyte subsets as
previously described (Baerlocher et al, 2006; Alter et al, 2012).
Clinical germline mutation testing was performed in Clinical
Laboratory Improvement Amendments-certified laboratories.
Statistical analysis
All statistical analyses were two-sided. We used Fisher’s exact
and Student’s t-test to compare pre- and post-treatment
parameters. P < 005 were considered significant. Analyses
were done with Microsoft Excel (2007 release) and STATA
Version 11 (StataCorp Release 11, College Station, TX, USA).
Results
Patient characteristics
The median age at study entry was 16 years (range
15–69 years) (Table I). Thirty-seven of the 44 patients (84%)
had a germline mutation in one of the known DC-causing
genes (11 DKC1, 12 TINF2, 5 TERT, 3 TERC, 2 WRAP53
[TCAB1], and 4 RTEL1) (Table II). Thirty-four of the 44
patients (77%) had single or multi-lineage cytopenia. Ten
(23%) had cytopenia with Hb >80 g/l but less than normal
for age, ANC between 05–15 9 109/l and/or platelets
between 30–150 9 109/l and did not require treatment.
Twenty-four patients (54%) had severe single or multi-lineage
cytopenia with Hb <80 g/l, ANC <05 9 109/l and/or plate-
lets <30 9 109/l. Eight patients with severe cytopenias were
not treated with androgens; four of these eight patients were
transfusion dependent until receiving HSCT, one was treated
with RBC and platelet transfusions as needed, two were






Number 44 28 16
Male:female 17:5 11:3 3:1
Median age,
years (range)
16 (15–69) 18 (25–69) 11 (15–47)
P. P. Khincha et al
2 Published 2014. This article is a U.S. Government work and is in the public domain in the USA. British Journal of Haematology
treated with immunosuppressive agents (but did not respond)
and one patient did not require treatment. Sixteen patients
with severe cytopenias were treated with androgens (14 oxy-
metholone, one fluoxymesterone and one nandrolone decan-
oate). Of these 16 treated patients, germline mutations were
known in 14 (88%) (3 DKC1, 6 TINF2, 1 TERC, 1 WRAP53
and 3 RTEL1) (Table II). The starting oxymetholone dose
was 05–1 mg/kg, which was increased or decreased based on
the patient’s haematological response. The maintenance
dose was the minimum effective dose and ranged from
05–27 mg/kg/d (median 15 mg/kg/d). Of the 16 patients
who received androgens, pre-treatment lipid panels were
available for 10, LFTs and measures of endocrine function
were available from 11, and complete blood counts (CBCs)
were available for all patients. Twenty-eight DC patients who
never received androgens served as controls. Germline
mutations were known in 22 (79%) of the controls (8 DKC1,
6 TINF2, 5 TERT, 2 TERC and 1 WRAP53) (Table II).
Haematological response
Eleven of the 16 patients (69%) treated with androgens
showed a haematological response, 10 to oxymetholone and
one to fluoxymesterone (Fig 1). All 11 patients who
responded had a Hb increment of ≥20 g/l from baseline
[median pre-treatment Hb 93 g/l (range 60–104 g/l) vs. post-
treatment Hb 116 g/l (range 94–130 g/l); P < 0001]. The
ANC improved in four out of the eight patients with an ANC
below 10 9 109/l at treatment initiation [median pretreat-
ment ANC 055 9 109/l (range 05–084 9 109/l); post treat-
ment ANC 1514 9 109/l (range 113–1985 9 109/l);
P < 001]. Nine of 15 patients (60%) who had a platelet count
<30 9 109/l prior to androgen therapy demonstrated an
androgen response with increase from a median platelet count
of 135 9 109/l (range 7–25 9 109/l) to 415 9 1 09/l (range
41–131 9 109/l); P < 001. The median time to response was
4 months (range 2–9 months) for Hb, 16 months (range
1–26 months) for ANC, and 14 months (06–75 months)
for platelets. A haematological response was observed in two
of three (67%) patients with DKC1 mutations, four of six
(67%) with TINF2, 1 of 1 (100%) with TERC, 1 of 1 (100%)
with WRAP53, and three of three (100%) with RTEL1
mutations. Neither of the two treated patients with unknown
genetic cause for DC responded to androgens.
The median duration of androgen therapy was 22 years
(range 04–10 years). Androgens were discontinued in 11
patients during the observation period. Four patients (one
on nandrolone and three on oxymetholone) failed to respond
after 4–5 months. Two patients on oxymetholone and G-CSF
discontinued therapy after 1 and 2 years of treatment
because of splenic peliosis (Giri et al, 2007). Three patients
stopped responding to oxymetholone after 23, 39, and
55 years of therapy. Treatment was discontinued at 26 and
55 years for a hypoechoic liver lesion with a non-diagnostic
biopsy and persistent transaminitis in one patient, and
behavioural problems/noncompliance in another. Five
haematological DC responders (one on fluoxymesterone,
four on oxymetholone) were still responding to treatment at
a median of 37 years (range 08–10 years) at the time these
data were analysed.
Telomere length in DC before and after androgens
Four DC patients who responded to androgen (three to oxy-
metholone and one to fluoxymesterone) therapy had telo-
mere length measurements prior to, and at a median of
26 years (range 08–78 years) after androgen treatment.
Post-androgen telomere lengths were consistently the same
or shorter than pre-androgen measurements in the total
lymphocyte population from all four patients (Fig 2A) and
in the four lymphocyte subsets measured (CD 20+ B cells,
CD 45+ Na€ıve T cells, CD 45- Memory T cells, CD 57+ Nat-
ural Killer cells; data not shown). Telomere lengths declined
over time (median 55 years, range 5–7 years) in five
untreated patients, as previously shown in this population
(Fig 2B) (Alter et al, 2012).
Lipid abnormalities
A fasting lipid panel was obtained in all 28 untreated patients
and in 13 of the 16 patients while on androgen therapy; 10
of the latter also had pre-androgen lipid data. All 13 DC
patients treated with androgens showed markedly abnormal
lipid profiles compared with their own pre-androgen values.
Table II. Genetic characteristics of dyskeratosis congenita patients by androgen treatment status and response.
Treated with androgens
Not treated TotalResponders Non responders % response
DKC1 2 1 67 8 11
TINF2 4 2 67 6 12
TERC 1 0 100 2 3
TERT 0 0 NA 5 5
WRAP53 1 0 100 1 2
RTEL1 3 0 100 0 3
Unknown 0 2 0 6 8
Total 11 5 69 28 44
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Total cholesterol was elevated (>518 mmol/l) in 54% after
androgens vs. 8% prior to therapy (P = 0001). Similarly, all
patients had significantly abnormally low HDL (100% on
androgens vs. 5% prior to treatment, P < 00001) and high
LDL (100% on androgens vs. 16% prior to treatment,
P < 00001), and high triglycerides (38% on androgens vs.
5% prior to treatment, P = 0008). All P values for lipid levels
on the treated patients compared with those never treated
were statistically significant (P < 00001) (Table III, Fig 3).
Liver function
Twenty-one of the 28 (75%) untreated DC patients had
elevated LFTs, suggesting possible underlying DC-related liver
disease. Six of 11 (55%) treated patients had pre-treatment
abnormalities in at least one liver parameter evaluated
(Table IV). There was no statistically significant difference in
liver function between treated versus never-treated DC
patients. Though pre- and post-treatment LFT parameters
did not differ statistically, liver enzyme elevation on andro-
gens was noted in eight (50%) treated patients, one of whom
had normal pretreatment liver function at the time of evalua-
tion. Dose reduction was advised when patients on andro-
gens developed an AST or ALT more than twice the upper
limit of normal. One patient continued to have good haemato-




Fig 1. Haematological response in all patients with DC treated with
androgens. The median is denoted by the solid horizontal line. (A)
Haemoglobin (g/l) (B) Absolute Neutrophil Count (9109/l) (C)
Platelet count (9109/l), DC, dyskeratosis congenita.
(A)
(B)
Fig 2. Longitudinal telomere lengths in patients with DC. (A) Pre-
and post-androgen lymphocyte telomere lengths in four DC patients.
The green line indicates the patient treated with fluoxymesterone.
The other three patients received oxymetholone. Legend reflects the
known germline mutation in each patient. (B) Lymphocyte telomere
lengths in five DC patients not treated with androgens. Legend
reflects the known germline mutation in each patient. DC, dyskera-
tosis congenita.
P. P. Khincha et al
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Androgen therapy was discontinued in one of 16 (6%)
patients due to persistent elevation of liver transaminases.
Structural changes in the liver and spleen
Among the 37 DC patients who underwent liver and spleen
ultrasound examinations, one treated patient (3%) developed
a hypoechoic liver lesion that was non-diagnostic on biopsy
but not suggestive of either an adenoma or liver fibrosis.
Two patients who received G-CSF combined with androgens
developed splenic peliosis leading to rupture requiring emer-
gent surgical care for one patient (Giri et al, 2007). No other
patients in our study reported concomitant use of growth
factors and androgens.
Bone changes
Six pre-pubertal male DC patients had accelerated growth
that crossed at least two percentile curves on the growth
Table IV. Liver function of untreated and treated dyskeratosis congenita (DC) patients.
Parameter (normal range) AST (0–59 u/l) ALT (5–30 u/l) Total Bilirubin (0–171 lmol/l) GGT (2–24 u/l)
DC: not treated
Number abnormal/Total patients (%) 4/40 (10%) 15/40 (38%) 10/40 (25%) 6/36 (17%)
Median (range) 25 (12–116) 26 (7–171) 1197 (342–41) 24 (0–114)
DC: treated
Number abnormal/Total patients (%) 2/13 (15%) 6/14 (43%) 3/14 (21%) 4/10 (40%)
Median (range) 31 (12–87) 29 (15–553) 1197 (342–2737) 17 (9–247)
P-value* NS NS NS NS
AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyl transpeptidase; NS, Not significant (P > 005).
P value calculated by Fisher exact test.
P ≤ 005 considered significant.
*Comparison between untreated and treated DC patients.











Number abnormal/Total patients (%) 3/38 (8%) 2/38 (5%) 6/37 (16%) 2/38 (5%)
Median (range) 394 (275–627) 127 (08–269) 214 (101–37) 072 (034–189)
DC: treated
Number abnormal/Total patients (%) 7/13(54%) 13/13 (100%) 13/13 (100%) 5/13 (38%)
Median (range) 518 (35–927) 039 (018–096) 451 (228–754) 112 (054–269)
P-value* 0001 <00001 <00001 0008
FA: treated
Number abnormal/Total Patients (%) 0/6 (0%) 3/6 (50%) 3/6 (50%) 1/6 (17%)
Median (range) 364 (347–451) 101 (07–197) 249 (223–285) 084 (033–202)
P-value† 004 002 002 NS
HDL, high density lipoprotein; LDL, low density lipoprotein; NS, Not significant (P > 005).
P value calculated by Fisher exact test.
P ≤ 005 considered significant.
*Comparison between untreated and treated DC patients.
†Comparison between post-androgen DC and FA patients.
Fig 3. Summary of lipid changes in patients with DC and FA treated
with androgens. DC, dyskeratosis congenita; FA, Fanconi anaemia;
HDL, high density lipoprotein; LDL, low density lipoprotein.
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chart during androgen treatment (Fig 4). One patient had
marked growth acceleration from the 10th percentile to
greater than the 97th percentile for height in a six-year per-
iod. Three patients on androgens developed bone fractures of
the femur, tibia, humerus and clavicle after reporting mini-
mal or no trauma (e.g., getting into a car). However, two
patients in the untreated group also had bone fractures, one
tibial fracture after minor trauma and one femur fracture
after minor trauma in a post-HSCT patient.
Endocrine function
All patients had normal thyroid function both prior to and
during androgen therapy, although we observed a significant
decrease in TBG in 10/11 (91%) patients after beginning
androgen treatment (P = 0004). All treated patients reported
masculinizing androgen effects; males reported priapism; and
female patients reported hirsutism and voice hoarseness. We
did not collect systematic information on behavioural com-
plications.
Comparison with Fanconi anaemia
As an additional comparison group, we also reviewed the
medical records for 11 patients with FA treated with andro-
gens (three males and eight females) enrolled in the same NCI
longitudinal IBMFS study. Median age at study entry for the
FA group was 13 years (range 6–34 years). Two FA patients
had single lineage and nine (82%) had multi-lineage cytope-
nia. Seven patients were treated with oxymetholone, two with
danazol, one each with nandrolone decanoate and dehydro-
epiandrosterone (DHEA). Two FA patients, one DHEA- and
Fig 4. Growth acceleration in six pre-pubertal
male dyskeratosis congenita patients on andro-
gen therapy. Growth charts from CDC website,
May 2000 (http://www.cdc.gov/growthcharts/
clinical_charts.htm). Legend reflects the known
germline mutation in each patient.
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one danazol-treated, had received oxymetholone in the past.
Haematological data were available on eight treated FA
patients, all of whom (100%) had a haematological response
with an increase in Hb of at least 20 g/l higher than the pre-
treatment value. Five of eight (63%) had a neutrophil response
and seven patients (71%) had a platelet response. Time to
response could not be determined due to lack of data.
Post-androgen lipid data were available from six of the 11
treated FA patients. Four (60%) had high LDL, low HDL or
high triglycerides while on androgens (Table III, Fig 3). Lipid
levels in FA patients could not be directly compared with the
levels in DC patients because FA patients were on substan-
tially lower doses of androgens at the time of evaluation
(median oxymetholone dose of 02 mg/kg/d [range
002–06]). Liver function abnormalities in the FA patients
were similar to those observed in DC patients. Five of six
(83%) FA patients had abnormal liver parameters before
treatment and eight of 10 (80%) androgen-treated patients
developed at least one elevated serum transaminase. Review
of records showed that like DC, FA patients had also
required androgen dose-adjustments for high liver transamin-
ases. None of the six FA patients who had TBG measurements
while on androgens demonstrated a change in TBG.
Discussion
Patients with DC have very high rates of BMF but may not
always be HSCT candidates, whether due to personal choice,
medical ineligibility or lack of suitable donors. Our study
suggests that androgen therapy for DC-related BMF may be
a reasonable therapeutic modality if carefully monitored and
thoughtfully considered either in patients unable to undergo
HSCT or as a bridge to HSCT further down the road.
It is very encouraging that 69% of our DC patients had a
haematopoietic response, with notable improvements in
erythroid and platelet lineages. Specifically, 14 of the 16 DC
patients evaluated in our study were treated with oxymetho-
lone, with two (14%) of them demonstrating a trilineage
response; six (43%) had erythroid and platelet lineage
responses (all of whom had normal pre-treatment ANC).
This is similar to previous FA reports (Alter & Kupfer, 1993;
Rose et al, 2014) and in our small FA cohort. Our patient
treated with danazol did not have a haematological response,
in contrast to a recent report of two patients with DC who
did respond (Islam et al, 2013).
Patients with DC in our study had a surprisingly high
prevalence of severe lipid profile abnormalities. This has nei-
ther been previously evaluated in DC nor reported in FA.
Androgen-treated FA patients in our cohort did not have
lipid abnormalities at the time of this evaluation, but their
androgen doses were much lower than those used in DC.
Abnormalities in lipid profile during androgen therapy for
different indications, such as chronic obstructive pulmonary
disease, constitutional growth retardation, muscle wasting or
body-building, have been well documented in the past
(Glazer, 1991; Shahidi, 2001). We cannot quantify the
long-term risk of atherosclerosis from the sustained lipid
profile abnormalities seen in our DC patients, but it is possi-
ble that annual monitoring of carotid intima-media thickness
by Doppler ultrasound may prove helpful in the future, to
identify early atherosclerotic changes so that timely discon-
tinuation of androgen therapy or initiation of lipid-lowering
therapy can be considered (Baldassarre et al, 2013).
Endocrine dysfunction is an important clinical concern for
all patients treated with androgens. While we observed statis-
tically significant decreased TBGs in treated DC patients,
their thyroid function was normal. Previous studies (Arafah,
1994; Tahboub & Arafah, 2009) suggest that in patients with
normal thyroid function, TBG levels markedly decrease after
initiation of androgen therapy, but the precise mechanism is
unknown.
Growth and development before, during and after andro-
gen therapy in pre-pubertal and adolescent patients should be
carefully monitored; patients and their parents need to under-
stand the potential for endocrine-related side effects, including
rapid bone growth, behaviour changes and masculinization. It
is also important to note that patients with DC may have an
increased prevalence of neuropsychiatric conditions (Rackley
et al, 2012) that could be exacerbated by androgen therapy.
Careful evaluation and management for behavioural compli-
cations of androgen therapy are warranted.
The occurrence of bone fractures in both treated and
untreated DC patients makes it difficult to discern whether
these events were treatment-related, an intrinsic component
of the disease phenotype, a combination of both or a conse-
quence of other unrecognized risk factors. The combination
of androgen-related accelerated bone growth and increased
muscle mass may have created a discrepancy between muscle
strength and bone mineralization which resulted in increased
skeletal fragility. It is also possible that telomere biology dis-
orders, such as DC, have a bony phenotype that is not yet
characterized. For example, a subset of patients with DC has
mutations in CTC1, a telomere-capping gene. In addition,
mutations in CTC1 also cause a disorder designated ‘Coats
plus’ (also known as cerebroretinal microangiopathy with
calcifications and cysts), in which some patients have abnor-
mal bone growth and poor bone healing, in addition to
features of DC (Anderson et al, 2012; Polvi et al, 2012). The
DC patients in our study did not have CTC1 mutations.
We found the expected age-related telomere attrition in
patients with DC both before and after androgen therapy,
observations which differ from recent case reports suggesting
that telomere attrition may be mitigated by androgen therapy
(Chen et al, 2012; Ziegler et al, 2012; Scheinberg, 2013). This
difference could be due to the small size of our cohort, the
sensitivity and specificity of the different telomere length
measurement methods (e.g., quantitative polymerase chain
reaction used by Scheinberg (2013), flow-FISH used by Chen
et al (2012) and Alter et al, 2012) and/or other clinical or
methodological differences between studies.
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A strength of this study is that, to our knowledge, it is the
largest systematic study of therapeutic response to and side
effects from androgen therapy for DC-related BMF. Our data
suggest that a large proportion of DC patients with BMF can
be given androgens safely, and can achieve a good haemato-
logical response. However, it is difficult to draw definitive
conclusions from a small, observational non-randomized
study. But, given the rarity of DC, a methodologically-rigor-
ous study design may be difficult to implement.
In conclusion, androgen therapy for BMF in DC is a rea-
sonable option in patients who are not HSCT candidates or as
bridging therapy while awaiting HSCT. A longer, prospective
study is needed to further characterize the observed adverse
effects. Studies using danazol, an attenuated androgen, are
underway in patients with FA, and various DC-related telo-
mere biology disorders (NCT01001598 and NCT01441037).
Until those results are available, we recommend that DC
patients receiving androgens for BMF have frequent monitor-
ing of their serum lipids, liver function, growth and develop-
ment, as well as biannual liver/spleen ultrasounds.
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